Topical diclofenac offers no extra benefit for post-PRK pain

Article

Oral diclofenac sufficiently manages pain after photorefractive keratectomy (PRK), and adding topical diclofenac 0.1% drops to a post-PRK oral diclofenac regimen does not add any additional pain-control benefit, according to recent research.

Oral diclofenac sufficiently manages pain after photorefractive keratectomy (PRK), and adding topical diclofenac 0.1% drops to a post-PRK oral diclofenac regimen does not add any additional pain-control benefit, according to research conducted in Mashhad and Tehran, Iran, and reported in Clinical & Experimental Ophthalmology.

The researchers studied 68 patients in a prospective, randomized, double-masked clinical trial. All of the patients were undergoing bilateral PRK for myopic correction.

Prior to their PRK procedures, all of the patients received two 100 mg doses of extended-release oral diclofenac. The patients were then randomized into two postoperative groups. One group received topical diclofenac 0.1% drops, 1 drop 2 hours preoperatively, and 1 drop 4 times each day for 3 days postoperatively. The other group received artificial tears.

On day 2 post-surgery, there was no statistically significant difference in patient-evaluated pain level, photophobia, or functional activity between the two groups. However, the group that received the artificial tears had significantly higher eyelid oedema and conjunctival injection levels than the group that received the diclofenac drops.

The researchers conclude that although the addition of topical diclofenac to a post-PRK pain regimen of oral diclofenac diminished local signs such as eyelid oedema and conjunctival injection, it did not help to alleviate post PRK-pain.

To view an abstract of the study, click here.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
© 2025 MJH Life Sciences

All rights reserved.